지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2018.12
- 수록면
- 102 - 107 (6page)
이용수
초록· 키워드
오류제보하기
Purpose: Cardiotoxicity is a serious late complication of breast cancer treatment. Individual treatment risk of specific drugs has been investigated. However, studies on the evaluation of the composite risk of chemotherapeutic agents are limited.
Methods: We retrospectively analyzed the medical records of breast cancer patients who received adjuvant treatment and had available serial echocardiography results. Patients were assigned to subgroups based on chemotherapy containing anthracyclines (A), anthracyclines and taxanes (A+T), and radiotherapy (RT). The development of cardiac disease and serial ejection fraction (EF) were reviewed. EF decline up to 10% from baseline was considered grade 1 cardiotoxicity and EF decline >20% or absolute value <50% was considered grade 2 cardiotoxicity. The most recent medical records and echocardiography results over 1 year of chemotherapy completion were also reviewed. Late cardiotoxicity was defined as a lack of recovery of EF decline or aggravated EF decline from baseline.
Results: In total, 123 patients were evaluated. A small reduction in EF was observed after chemotherapy in both chemotherapy groups. There were no significant differences between groups A and A+T in EF decline following chemotherapy. We could not find any differences in composite risk between the chemotherapy groups and the RT group during follow-up. Late cardiotoxicity was seen in 15.45% of patients. During follow-up, three patients were diagnosed with dilated cardiomyopathy.
Conclusion: There was no significant composite risk elevation following adjuvant treatment of breast cancer. However, late cardiotoxicity was considerable and further research in this direction is necessary.
Methods: We retrospectively analyzed the medical records of breast cancer patients who received adjuvant treatment and had available serial echocardiography results. Patients were assigned to subgroups based on chemotherapy containing anthracyclines (A), anthracyclines and taxanes (A+T), and radiotherapy (RT). The development of cardiac disease and serial ejection fraction (EF) were reviewed. EF decline up to 10% from baseline was considered grade 1 cardiotoxicity and EF decline >20% or absolute value <50% was considered grade 2 cardiotoxicity. The most recent medical records and echocardiography results over 1 year of chemotherapy completion were also reviewed. Late cardiotoxicity was defined as a lack of recovery of EF decline or aggravated EF decline from baseline.
Results: In total, 123 patients were evaluated. A small reduction in EF was observed after chemotherapy in both chemotherapy groups. There were no significant differences between groups A and A+T in EF decline following chemotherapy. We could not find any differences in composite risk between the chemotherapy groups and the RT group during follow-up. Late cardiotoxicity was seen in 15.45% of patients. During follow-up, three patients were diagnosed with dilated cardiomyopathy.
Conclusion: There was no significant composite risk elevation following adjuvant treatment of breast cancer. However, late cardiotoxicity was considerable and further research in this direction is necessary.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (22)
참고문헌 신청
[학술지(정기간행물)] - Wilbur J / 2015 / Surveillance of the adult cancer survivor / Am Fam Physician 91 : 29 ~ 36
[학술지(정기간행물)] - Abdel-Qadir H / 2017 / A Population-based study of cardiovascular mortality following early-stage breast cancer / JAMA Cardiol 2 : 88 ~ 93
[학술지(정기간행물)] - Park NJ / 2017 / Cardiovascular disease and mortality after breast cancer in postmenopausal women: results from the Women’s Health Initiative / PLoS One 12 : e0184174 ~
[학술지(정기간행물)] - Stava C / 2006 / Health profiles of 814very long-term breast cancer survivors / Clin Breast Cancer 7 : 228 ~ 236
[학술지(정기간행물)] - Zagar TM / 2016 / Breast cancer therapy-associated cardiovascular disease / Nat Rev Clin Oncol 13 : 172 ~ 184
[학술지(정기간행물)] - Abdel-Qadir H / 2017 / A Population-based study of cardiovascular mortality following early-stage breast cancer / JAMA Cardiol 2 : 88 ~ 93
[학술지(정기간행물)] - Park NJ / 2017 / Cardiovascular disease and mortality after breast cancer in postmenopausal women: results from the Women’s Health Initiative / PLoS One 12 : e0184174 ~
[학술지(정기간행물)] - Stava C / 2006 / Health profiles of 814very long-term breast cancer survivors / Clin Breast Cancer 7 : 228 ~ 236
[학술지(정기간행물)] - Zagar TM / 2016 / Breast cancer therapy-associated cardiovascular disease / Nat Rev Clin Oncol 13 : 172 ~ 184
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Breast Cancer and Therapy-Related Cardiovascular Toxicity
Journal of Breast Cancer
2024 .06
-
Comparison of the Beneficial Effects of Adjuvant Chemotherapy among Young and Old Aged Breast Cancer Patients
Journal of Breast Disease
2019 .01
-
The efficacy of chemotherapy in the patients with stage II colon cancer associated with number of high-risk factors
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
-
Adjuvant Chemotherapy
대한외과학회 학술대회 초록집
2021 .11
-
Coenzyme Complex Decreased Cardiotoxicity When Combined with Chemotherapy in Treating Elderly Patients with Gastrointestinal Cancer
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Evaluation of the Survival Benefit of Different Chemotherapy Regimens in Patients with T1-2N0 Triple-Negative Breast Cancer
Journal of Breast Cancer
2015 .01
-
Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage Ⅲ colon cancer
Annals of Surgical Treatment and Research
2015 .08
-
비전이성 유방암 수술환자의 보조화학요법 현황
병원약사회지
2021 .01
-
Quality of life changes during adjuvant chemotherapy in patients with colon cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2016 .06
-
항암치료 중인 유방암환자를 대상으로 한 운동중재에 관한 국내 연구동향
Asian Oncology Nursing
2015 .12
-
Correlation of UGT2B7 Polymorphism with Cardiotoxicity in Breast Cancer Patients Undergoing Epirubicin/Cyclophosphamide-Docetaxel Adjuvant Chemotherapy
Yonsei Medical Journal
2019 .01
-
Prognostic factors in patients with locally advanced breast cancer treated with neoadjuvant taxane-anthracycline combination chemotherapy
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2015 .12
-
Neoadjuvant Chemotherapy versus Adjuvant Chemotherapy in Breast Cancer Patients: Analysis of Breast Conserving Rate and De-escalation of Axillary Surgery in 5141 Korean Women
대한외과학회 학술대회 초록집
2020 .11
-
Chemotherapy and Radiation Treatment for Breast Reconstruction Patients
대한외과학회 학술대회 초록집
2019 .10
-
Changes of Cognitive Function and Fatigue following Chemotherapy in Patients with Gastrointestinal Cancer: A Prospective Controlled Study
Asian Oncology Nursing
2019 .09
-
Hyperglycemia during adjuvant chemotherapy as a prognostic factor in non-diabetic breast cancer patients
대한임상종양학회 학술대회지
2020 .07
-
유방암에 대한 한양방 병용 치료 증례 보고 1례
대한한방내과학회지
2017 .01
-
Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia-Pacific Breast Initiatives I and II
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
유방암 환자에서 항암화학요법 후 인지기능과 후각기능의 변화 : 예비연구
생물치료정신의학
2017 .06
이 논문의 저자 정보
이 논문과 함께 이용한 논문
Massive Morel-Lavallée Lesion Mimicking Acute Limb Ischemia
Jieon Go
,
Sangchul YUN
,
Chul Han Kim
외 4명
대한외과학회 학술대회 초록집
2018
.11
Revision to Roux-en Y Gastric Bypass for Weight Loss Failure Patients after Sleeve Gastrectomy; Technical Consideration
Dae Geun Pa
,
k
,
Yong Jin Kim
대한외과학회 학술대회 초록집
2018
.11
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2019-514-000326827